RSPO1 PROTEIN NO FURTHER A MYSTERY

These trials showed clinically considerable pharmacokinetic interactions [7] characterised by a lessen in the clearance in the anticancer drug and as a result elevated exposure. The interpretation of subsequent phase II and III clinical trials was difficult because it was not possible to administer precisely the same dose of chemotherapy inside the